Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 6/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688175 | 0.82 | NOS3 (0.56) | TRPA1NOS3NOS1NOS2HTR2A | |
| SCHEMBL124176 | 0.79 | CYP1A2 (0.44) | TRPA1MAOAMAOBNOS3NOS1 | |
| SCHEMBL8429416 | 0.79 | TRPA1 (0.42) | TRPA1MAOAMAOBHRH4NOS3 | |
| SCHEMBL6713670 | 0.78 | TRPA1 (0.41) | TRPA1MAOAMAOBHRH4NOS3 | |
| SCHEMBL11227860 | 0.76 | TRPA1 (0.40) | TRPA1HRH4NOS3NOS1NOS2 | |
| SCHEMBL2086425 | 0.74 | TRPA1 (0.47) | TRPA1MAOAMAOBHRH4NOS3 | |
| SCHEMBL22081972 | 0.73 | CYP1A2 (0.62) | TRPA1MAOAMAOBCYP1A2HTR2A | |
| SCHEMBL29881712 | 0.73 | — | — | |
| SCHEMBL109650 | 0.73 | CYP1A2 (0.62) | TRPA1MAOAMAOBCYP1A2HTR2A | |
| SCHEMBL1525601 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080007158-A1 | Linear Polysiloxanes, Silicone Composition, and Organic Light-Emitting Diode | FAROOQ OMAR | 2008-01-10 | — | — | US | claimed |
| EP-1789474-A1 | LINEAR POLYSILOXANES, SILICONE COMPOSITION, AND ORGANIC LIGHT-EMITTING DIODE | Dow Corning Corporation (US) | 2007-05-30 | — | — | EP | claimed |
| WO-2006001874-A1 | LINEAR POLYSILOXANES, SILICONE COMPOSITION, AND ORGANIC LIGHT-EMITTING DIODE | DOW CORNING CORPORATION (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050049376-A1 | High refractive index, uv-curable monomers and coating compositions prepared therefrom | GENERAL ELECTRIC COMPANY | 2005-03-03 | — | — | US | claimed |
| EP-0471236-B1 | Imidazopyridine derivatives and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-03-15 | — | — | EP | claimed |
| EP-0471236-A1 | Imidazopyridine derivatives and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-02-19 | — | — | EP | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
| CN-113039191-B | Nucleotide analogues | 奇异基因组学系统公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2024145687-A1 | BIOREACTIVE PROTEINS CONTAINING AN UNNATURAL AMINO ACID AND ARGININE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-04 | — | — | WO | disclosed |
| CN-118251492-A | PMP 22-targeting compounds for the treatment of summer-Mary-Tuber disease | 诺华股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240200041-A1 | Modified Pyrococcus Polymerases and Uses Thereof | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-06-20 | — | — | US | disclosed |
| EP-3538101-B1 | INHIBITORS OF CANCER AND/OR METASTASIS | UNIV VIRGINIA COMMONWEALTH (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240188436-A1 | COMPOSITION, USE OF SAID COMPOSITION AS LIGHT-EMITTING COMPOSITION, FILM, USE OF SAID FILM AS LIGHT-EMITTING FILM, ORGANIC ELECTROLUMINESCENT ELEMENT, METHOD FOR DESIGNING COMPOSITION, AND PROGRAM FOR IMPLEMENTING SAID DESIGN METHOD | KYULUX, INC. (JP) | 2024-06-06 | — | — | US | disclosed |
| US-4820694-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0262905-A2 | Modifications of 3-0-demethyl-mycinose in macrocin and lactenocin | ELI LILLY AND COMPANY (US) | 1988-04-06 | — | — | EP | disclosed |
| EP-0262904-A2 | Modifications of mycinose and 3-0-demethylmycinose in tylosintype macrolides | ELI LILLY AND COMPANY (US) | 1988-04-06 | — | — | EP | disclosed |
| EP-0262903-A2 | New acyl derivatives of 20-modified tylosin and desmycosin compounds | ELI LILLY AND COMPANY (US) | 1988-04-06 | — | — | EP | disclosed |
| US-4604380-A | ADMINISTERING TO TREAT BACTERIAL OR MYCOPLASMAL INFECTION | ELI LILLY AND COMPANY (US) | 1986-08-05 | — | — | US | disclosed |
| EP-0188373-A2 | Macrolide derivatives | ELI LILLY AND COMPANY (US) | 1986-07-23 | — | — | EP | disclosed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049376-A1 | High refractive index, uv-curable monomers and coating compositions prepared therefrom | MACF1, WASF2, THEM6 | TRPA1 3100/4885MAOA 3034/4885MAOB 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.